To determine the frequency of serious pulmonary and hepatic adverse events (AEs) in persons aged 65 and older prescribed nitrofurantoin. DESIGN: Retrospective electronic health record (EHR) audit of nitrofurantoin prescriptions and associated AEs. SETTING: Urban academic medical center. PARTICIPANTS: All inpatients and outpatients aged 65 and older prescribed nitrofurantoin from January 1, 2010, to December 31, 2014. MEASUREMENTS: The number of nitrofurantoin prescriptions and pulmonary and hepatic AEs associated with nitrofurantoin use was acquired by data extraction from EHRs. RESULTS: Of 3,400 individuals aged 65 and older prescribed nitrofurantoin during the study period, 641 were identified as possibly having one of five targeted symptoms or disease complications (pulmonary and hepatic) associated with nitrofurantoin. After a detailed chart audit, 89% were deemed to have no adverse reaction, 7% had a minor side effect or allergy, and 3.9% met criteria for suspicion of a nitrofurantoin-induced AE, five of whom were rated as being highly suspicious for nitrofurantoin toxicity; four of the five were identified with pulmonary toxicity and one with hepatotoxicity. Four of five of these individuals used nitrofurantoin chronically. CONCLUSION: Nitrofurantoin was prescribed for 3,400 individuals aged 65 and older during the 5-year study period. Serious side effects appeared to be uncommon, but chronic use appeared to be at greater risk. J Am Geriatr Soc 65:1316-1320, 2017.
N itrofurantoin use in older adults has been controversial. Nitrofurantoin prescriptions have dramatically risen since guideline changes by the Infectious Disease Society of America (IDSA) recommended nitrofurantoin as first-choice treatment for acute uncomplicated cystitis and pyelonephritis in 2011 in premenopausal women. 1 Although the report noted that urinary tract infections (UTIs) in postmenopausal women without urological abnormalities or those with well-controlled diabetes mellitus could be considered to have uncomplicated UTIs, the committee specifically noted that these individuals were outside the scope of the ISDA guidelines. For premenopausal women, the ISDA concluded that nitrofurantoin was the recommended choice because of minimal bacterial resistance, lower propensity for development of drug-resistant organisms, and the drug's effectiveness, which is comparable to 3 days of trimethoprim with sulfamethoxazole. 1 Nitrofurantoin remains listed as a potentially inappropriate medication for older adults in the American Geriatrics Society (AGS) Beers Criteria. 2 It was first added to the Beers list in 2002, when the panel of experts wrote that there was "potential for renal impairment and safer alternatives available" and assigned a severity rating of high. 3 In a 2012 Beers update, the rationale for listing included potential for pulmonary toxicity and lack of efficacy in individuals with creatinine clearance less than 60 mL/min per 1.73 m 2 resulting in adequate drug concentration in urine, 4 but evidence of lack of efficacy in individuals with creatinine clearance less than 60 mL/min per 1.73 m 2 has been questioned, 5 and the 2015 Beers update has been modified to recommend avoidance when creatinine clearance is less than 30 mL/min per 1.73 m 2 .
2
In addition, the committee's rationale for avoiding nitrofurantoin included pulmonary toxicity, hepatotoxicity, and peripheral neuropathy, with particular unease about long-term use while safer alternatives are available. 2 The strength of the recommendation from the AGS Beers expert panel remained strong, but the quality of evidence was downgraded from moderate to low.
Two of the most serious nitrofurantoin-associated adverse reactions are pulmonary and hepatic. [6] [7] [8] [9] Because of published clinical reports are limited, it was decided to explore how often pulmonary and hepatic adverse events (AEs) occurred in individuals aged 65 and older prescribed nitrofurantoin in a large multidisciplinary academic health system. By doing so, it was hoped that a better appreciation would be gained of how often nitrofurantoin results in serious adverse reactions and thereby inform physician decisions regarding the use and safety of nitrofurantoin in older adults.
METHODS

Study Design and Population
All individuals aged 65 and older prescribed nitrofurantoin at University of Texas Southwestern Medical Center clinics or hospitals (University Hospital, Zale-Lipshy Hospital) from January 1, 2010, to December 31, 2014, were identified from electronic health records (EHRs) (Epic Systems Corporation, Verona, WI). Prescriptions are captured regardless of the site origination (hospital, clinic, home, other) and irrespective of the location of the receiving pharmacy. Most prescriptions are e-prescribed, but telephone and printed prescriptions are also recorded in the system.
Prescription of nitrofurantoin associated with International Classification of Diseases, Ninth Revision (ICD-9) codes for dyspnea (786.09), pulmonary fibrosis (515), cholestatic jaundice (782.4), chronic hepatitis (571.40), or hepatotoxicity (575.3) helped identify individuals suspected of serious nitrofurantoin-induced AEs, who were selected for further direct chart audit. Study data electronically extracted included age, sex, number of capsules (<30, ≥30), number of individual prescriptions per person, allergy to nitrofurantoin, and estimated glomerular filtration rate (eGFR) (<60, ≥60 mL/min per 1.73 m 2 ).
Determination of Nitrofurantoin-Associated AEs
Two medical students (KC, ES) manually audited the EHRs of patients prescribed nitrofurantoin who had one of the suspect diagnostic ICD-9 codes using a decision matrix to systematically grade the likelihood of a nitrofurantoin-associated AE to minimize subjectivity. An AE had to occur within 6 months after episodic prescription of nitrofurantoin or up to 1 year after cessation of prophylactic use.
The medical record was then inspected for the presence of acute or chronic problems that could explain the symptoms and for any investigation or assessment of a nitrofurantoin-induced AE. The reviewers independently categorized the AE into seven categories (Table 1) . If discordance occurred between reviewers, a third reviewer, a senior faculty physician (CDR), examined the chart, and the category was assigned based on the majority.
Individuals classified as high suspicion were determined to have no other underlying condition or acute cause to explain their symptoms after the case was clinically investigated (e.g., chronically taking nitrofurantoin or developed pulmonary fibrosis, all other causes excluded, symptoms improved after cessation of nitrofurantoin).
Possible A individuals had an underlying condition to explain their symptoms (e.g., dyspnea attributed to chronic obstructive pulmonary disease, dyspnea worsened on nitrofurantoin but improved after cessation of nitrofurantoin) and the individual returned to previous baseline after nitrofurantoin cessation. The Possible B cohort had no relevant underlying condition and no definitive evidence for an acute explanation of their symptoms (e.g., individual in the hospital for dyspnea after taking nitrofurantoin with many possible etiologies for dyspnea; nitrofurantoin as a cause neither confirmed nor denied). The Possible C cohort consisted of individuals with no underlying conditions or acute cause to explain their symptoms who were not investigated clinically (e.g., individual called during short course of nitrofurantoin reporting transient symptoms and stopped nitrofurantoin).
Nitrofurantoin allergic reactions were noted when pruritus, rash, swelling, or anaphylaxis occurred. Minor adverse reactions were categorized as mild nonspecific for complaints such as nausea, diarrhea, and headache. No AEs were reported if chart documtentation revealed minimal exposure, such as that the individual was prescribed three doses or less as suppressive treatment before a urological procedure or lack of documentation of an AE.
For individuals with suspected adverse reactions, age, sex, and kidney function (eGFR) were evaluated as contributing factors to nitrofurantoin-associated AEs. Dosage and maximum length of nitrofurantoin therapy were obtained using chart review.
After the initial evaluation and the probability determination of a nitrofurantoin AE, those classified as high or possible suspicion (A, B, C) for drug toxicity were assessed using the Naranjo Adverse Drug Reaction Probability Scale. Although the scale was developed for use in controlled trials and registration studies of new medications but not for retrospective studies, 10 the scoring was used to provide a degree of consistency of the evaluation. Total scores range from À4 to 13. Score from 1 to 4 are interpreted as possible drug reactions, 5 to 8 as probable drug reactions, and 9 to 13 as definite drug reactions. Scores of 0 or less indicate a doubtful adverse drug reaction. 
RESULTS
Of 3,400 individuals aged 65 and older (average age 76.5, range 65-103) prescribed nitrofurantoin during the study period, 641 were initially identified as having one to five target ICD-9 codes associated with a nitrofurantoin-associated AE. After manual chart inspection of these 641 suspected cases, 89% were deemed to have no drug-related AE, 5.1% had a minor side effect, 1.9% were allergic reactions, and 3.9% (25/641) were identified as possible pulmonary or hepatic nitrofurantoin-induced AEs. Five (0.8%) of the 25 possible serious AE cases were rated as high suspicion for nitrofurantoin toxicity and 20 as possible suspicion for an adverse drug effect (3.1%) ( Table 2) . Of the high suspicion cases, four were identified with pulmonary toxicity and one with hepatotoxicity; four of the five high suspicion cases used nitrofurantoin chronically. Four individuals with existing interstitial lung disease worsened on nitrofurantoin, accounting for four of the seven (57%) Possible A individuals.
AEs are shown in Figure 1 according to age, sex, drug exposure, and eGFR. There were no differences between the three age groups (P = .34), but a difference in sex between the 25 individuals with possible AEs was noted; women were more likely to have a possible AE (P = .04), although there was only one man in this category. eGFR was available only for the 25 individuals who were suspected of having nitrofurantoin-induced AEs, but the distribution above and below 60 mL/min per 1.73 m 2 appeared similar (Figure 1) .
When evaluating chronicity of use, it was found that 80% (4/5) of high suspicion individuals took nitrofurantoin for at least 1 month, whereas 14% of Possible A, 40% of possible B, and none of Possible C individuals received long-term nitrofurantoin.
When the Naranjo Adverse Drug Reaction Probability Scale was used, all high suspicion individuals had a scored of 4 and were considered to have a possible reaction. One Possible B individual had a score of 4, the other 19 possible cases had a score of 1 to 3, and none had a score of 0 or less.
DISCUSSION
Despite the placement of nitrofurantoin on the Beers list, it is commonly prescribed in individuals aged 65 and older in a large multispecialty academic health system. Of the 3,400 individuals prescribed nitrofurantoin, 25 were identified over a 5-year period with pulmonary or hepatic diagnoses possibly associated with nitrofurantoin, five of which were felt to be highly likely to be a serious nitrofurantoin-induced AE. Overall, 0.7% (25/3,400) of individuals had possible serious pulmonary or hepatic AEs, and 0.15% (5/3,400) were classified as highly likely to have had a serious lung or liver reaction. The majority of high suspicion cases used nitrofurantoin chronically; the most common reasons as discerned according to chart inspection were for neurogenic bladder and idiopathic recurrent UTIs. In a previous study, pulmonary toxicity due to nitrofurantoin occurred in 0.001% of individuals and hepatic toxicity due to nitrofurantoin occurred in 0.0003%. 11 A recent systematic review 12 found no pulmonary or hepatotoxic events related to nitrofurantoin in 4,807 individuals from 27 controlled trials, although the trials were of shortterm use and predominantly in younger individuals. Overall, toxicity was 5% to 16% in the 17 of 27 studies reporting toxicity and was mostly mild, reversible gastrointestinal side effects. A recently published study 13 did not find an overall greater risk of lung injury in individuals given nitrofurantoin than in those given other antimicrobials for cystitis, although the group taking nitrofurantoin for at least 14 days had a higher risk than those taking it for a shorter duration. 13 The current study results may be skewed because of possible preexclusion of nitrofurantoin prescriptions to individuals with a low GFR, although despite recommendations during the time of the study to avoid use in older adults and in particular in those with creatinine clearance less than 60 mL/min per 1.73 m 2 , nitrofurantoin use was common. The 25 individuals with possible AEs were almost equally divided between those with an eGFR above and below 60 mL/min per 1.73 m 2 ( Figure 1 ). Treatment failure, which has been a concern with use of nitrofurantoin in older populations, was not evaluated. Findings from a recent study in woman aged 65 and older treated with nitrofurantoin for UTIs found no difference in treatment response with mild or moderate reduction in eGFR.
14 Although peripheral neuropathy is another serious AE associated with nitrofurantoin use, it was decided not to include ICD codes for peripheral neuropathy because of the potential difficulty assigning nitrofurantoin causation for this common problem in older adults because there may have been other confounders such as diabetes mellitus, alcohol consumption, and idiopathic neuropathy. Nonetheless, by omitting this potential side effect, a common serious reaction to nitrofurantoin use may have been underreported. No evidence of drug-induced neuropathy was found in the 641 charts reviewed for possible pulmonary or hepatic complications.
There are several limitations to this study. This retrospective review of EHRs depended on documentation of complaints and coding, medication adherence, and followup. Lack of proper documentation could have led to inaccurate reporting of AEs. If individuals developed side effects and did not return to the health system, their events would not have been captured. In addition, medication adherence was not confirmed using pill count or other measures but relied solely on prescribing information. Furthermore, the retrospective analysis did not allow for interviews or prospectively evaluate data, which would be particularly helpful to assess adverse drug events; likewise, retrospective analysis did not provide the medical reasoning for nitrofurantoin selection. An effort was made to minimize subjectivity by using multiple chart reviewers and a decision matrix; interpretation of AEs could be a source of incidence under-or overreporting. Lastly, limited demographic information may make application of the findings to individual practitioners difficult. The 0.8% to 4% incidence of AEs reported here is of concern but should not prohibit nitrofurantoin prescriptions in older adults. Overall, the findings support the recently updated Beers Criteria guidelines, 2 which advocate avoiding chronic use in older adults and in individuals with creatinine clearance less than 30 mL/min per 1.73 m 2 , but because individuals younger than 65 were not included in the study, it could not be determined whether there were age-related differences in hepatic and pulmonary complications. The initial inclusion of nitrofurantoin on the Beers List was at least partially based on lack of efficacy with age-related decline in renal function, so it is possible that its inclusion may no longer be justified.
In summary, these findings suggest that individuals with chronic lung disease (e.g. interstitial lung disease, pulmonary fibrosis) should avoid nitrofurantoin and that particular care should be taken when prescribing long-term use, but little evidence to prohibit short-term use of nitrofurantoin was found. Although caution should be exercised with all medications, it is hoped that this analysis will stimulate greater reporting and risk assessment of nitrofurantoin use and provide more-tangible data to inform providers and clarify the risk of AEs associated with nitrofurantoin in older adults.
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